Early results from the largest ever randomised trial for lung cancer, using a blood test that detects autoantibody biomarkers, will be released on 7th September at the International Association for the Study of Lung Cancer’s 16th World Conference on Lung Cancer. The initial results of the NHS Scotland ECLS study of 10,000 high-risk smokers demonstrate a higher than expected cancer detection rate (sensitivity) of 81%, with a specificity (chance that a negative test excludes lung cancer) of 91%.

The ECLS study has recruited almost 10,000 patients to date, and the study will close in 2016 with 12,000 patients, with final results being available after two years follow up. The presentation to the World Lung Cancer Conference on 7th September will show an encouraging number of early stage lung cancers being detected by the EarlyCDT-Lung blood test from Oncimmune (Nottingham, UK).

Geoffrey Hamilton-Fairley, CEO of Oncimmune Limited, said: “If these results continue, it will further underpin the rationale of the ECLS study – namely that screening with EarlyCDT-Lung can be effective for the early detection of lung cancer, helping to save lives and money. We look forward to ECLS reporting updates on an ongoing basis.”

Prof Gordon Wishart, Medical Director of Check4Cancer Limited, said: “We are delighted by these exciting early results from the Scottish Lung Cancer Trial, and look forward to further updates from the trial during the coming years. As a leading provider of innovative early detection cancer tests for the corporate and private market in the UK and abroad, Check4Cancer are proud to have been working with Oncimmune to make the EarlyCDT-Lung test available to our clients since Q1 2013. In May 2013, Check4Cancer ran an extremely successful “Love Your Lungs” lung cancer awareness and early detection programme for Hewlett Packard, with engagement of more than 2500 employees in the UK & Ireland. We look forward to continuing to work closely with Oncimmune to deliver the EarlyCDT-Lung test to our clients”.